Brand-name drug and biologic manufacturers engage in anticompetitive behaviors to keep lower-cost alternatives off the market. The abuse of tactics such as pay-for-delay patent settlements, product hopping, and citizen petitions allows manufacturers to perpetuate significant profit by extending monopoly protections and preventing patient access to more affordable drugs.
